Na Zhang
Research Subjects
Na Zhang has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Wei Wei
Department of Rheumatology and Immunology, Tianjin Medical University General Hospital
4 shared publications - Wenwen Sun
Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin 300052, China; Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin 300052, China
2 shared publications - Xiaofeng Zeng
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
2 shared publications Caixin Wu
1 shared publication- Chen Zhang1 shared publication
- Chenning Zhang
Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 21 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial
Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been established in clinical trials. In this multicentre, double-blind, phase IIb trial, 152 patients with active SLE were randomised (1:1:1:1) to receive subcutaneous IL2 (0.2, 0.5, or 1.0 million IU) or placebo every other day for 12 weeks, then weekly for another 12 weeks. At week 12, SRI-4 response rates were higher in the IL2 1 M IU (69.7%), 0.5 M IU (64.7%), and 0.2 M IU (42.9%) groups than the placebo control group (23.5%). Notably, these differences persisted until week 24 (P < 0.001). Moreover, achievement of LLDAS increased in a dose-dependent manner. Patients who received 1 M IU also showed significant reductions in PGA scores, anti-dsDNA antibody titres and prednisone dosages. Infection rates were lower in the IL2 groups compared with placebo. Ld-IL2 drove the expansion of regulatory T cells (Tregs) and altered Treg/effector T cell ratios. These findings highlight the dose-dependent efficacy of IL2 with a favourable safety profile. (Clinicaltrials.gov registration number: NCT04077684).
- 21 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessLow dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial
Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been established in clinical trials. In this multicentre, double-blind, phase IIb trial, 152 patients with active SLE were randomised (1:1:1:1) to receive subcutaneous IL2 (0.2, 0.5, or 1.0 million IU) or placebo every other day for 12 weeks, then weekly for another 12 weeks. At week 12, SRI-4 response rates were higher in the IL2 1 M IU (69.7%), 0.5 M IU (64.7%), and 0.2 M IU (42.9%) groups than the placebo control group (23.5%). Notably, these differences persisted until week 24 (P < 0.001). Moreover, achievement of LLDAS increased in a dose-dependent manner. Patients who received 1 M IU also showed significant reductions in PGA scores, anti-dsDNA antibody titres and prednisone dosages. Infection rates were lower in the IL2 groups compared with placebo. Ld-IL2 drove the expansion of regulatory T cells (Tregs) and altered Treg/effector T cell ratios. These findings highlight the dose-dependent efficacy of IL2 with a favourable safety profile. (Clinicaltrials.gov registration number: NCT04077684).
- Top Cited PapersOpen Access
- 1 January 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (1) , 83
Semiquantitative HRCT scoring: a reliable predictor of rapidly progressive interstitial lung disease in patients with anti-MDA5 positive dermatomyositis
Anti-melanoma differentiation-associated gene 5 positive dermatomyositis (anti-MDA5 DM) is strongly linked to rapidly progressive interstitial lung disease (RP-ILD), which is associated with high early mortality. This study aimed to explore the feasibility of using semiquantitative visual scoring methods on high-resolution computed tomography (HRCT) to assess RP-ILD in anti-MDA5 DM patients, and to develop a risk prediction model for RP-ILD, given the poor prognosis of RP-ILD in anti-MDA5 DM. The data of patients with anti-MDA5 DM were retrospectively analyzed. Seven HRCT-based semiquantitative scoring methods were used to assess the extent of interstitial lung disease (ILD), and the correlation of each method with the pulmonary function tests (PFTs) was analyzed. The diagnostic performance of each method for RP-ILD was also evaluated. A nomogram model was developed to predict RP-ILD risk. In total, 67 patients with anti-MDA5 DM were included in the study. Methods 1, 2, 4, 5, and 6 significantly distinguished RP-ILD from non-RP-ILD (P<0.05). Method 1 showed the highest correlation with the PFTs and the best diagnostic performance for RP-ILD [area under the curve (AUC) =0.766, P<0.001]. The least absolute shrinkage and selection operator logistic regression analysis identified male sex, an advanced age at onset, fever, a decreased normal extent in the left lower lung zone, an increased consolidation extent in the left middle lung zone, and elevated C-reactive protein as predictors of RP-ILD. These six predictors were used to construct a prediction model, which had an AUC of 0.842 based on internal validation, and showed good predictive ability and clinical applicability after the calibration and clinical decision curve analyses. Semiquantitative visual scoring based on HRCT can effectively assess the severity of ILD in anti-MDA5 DM patients. A predictive model for RP-ILD that incorporates imaging and clinical information has potential for clinical application.
- 1 January 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (1) , 83
Top Cited PapersOpen AccessSemiquantitative HRCT scoring: a reliable predictor of rapidly progressive interstitial lung disease in patients with anti-MDA5 positive dermatomyositis
Anti-melanoma differentiation-associated gene 5 positive dermatomyositis (anti-MDA5 DM) is strongly linked to rapidly progressive interstitial lung disease (RP-ILD), which is associated with high early mortality. This study aimed to explore the feasibility of using semiquantitative visual scoring methods on high-resolution computed tomography (HRCT) to assess RP-ILD in anti-MDA5 DM patients, and to develop a risk prediction model for RP-ILD, given the poor prognosis of RP-ILD in anti-MDA5 DM. The data of patients with anti-MDA5 DM were retrospectively analyzed. Seven HRCT-based semiquantitative scoring methods were used to assess the extent of interstitial lung disease (ILD), and the correlation of each method with the pulmonary function tests (PFTs) was analyzed. The diagnostic performance of each method for RP-ILD was also evaluated. A nomogram model was developed to predict RP-ILD risk. In total, 67 patients with anti-MDA5 DM were included in the study. Methods 1, 2, 4, 5, and 6 significantly distinguished RP-ILD from non-RP-ILD (P<0.05). Method 1 showed the highest correlation with the PFTs and the best diagnostic performance for RP-ILD [area under the curve (AUC) =0.766, P<0.001]. The least absolute shrinkage and selection operator logistic regression analysis identified male sex, an advanced age at onset, fever, a decreased normal extent in the left lower lung zone, an increased consolidation extent in the left middle lung zone, and elevated C-reactive protein as predictors of RP-ILD. These six predictors were used to construct a prediction model, which had an AUC of 0.842 based on internal validation, and showed good predictive ability and clinical applicability after the calibration and clinical decision curve analyses. Semiquantitative visual scoring based on HRCT can effectively assess the severity of ILD in anti-MDA5 DM patients. A predictive model for RP-ILD that incorporates imaging and clinical information has potential for clinical application.
- Open Access
- 16 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Pulpotomy for teeth with irreversible pulpitis in immature permanent teeth: a retrospective case series study
To evaluate the success of pulpotomy in treating immature permanent teeth with irreversible pulpitis. This case series included patients with irreversible pulpitis admitted to the Department of Oral Medicine at the author’s Hospital between 2015 and 2020. The pulpotomies were carried out by clinicians with > 5 years of working experience. The follow-up findings and radiographic images were reviewed by two attending dentists. This study included 49 teeth from 48 children (25 boys and 23 girls). The follow-up was 23.3 ± 6.8 months (from 12 to 40 months). The success rate of pulpotomy was 85.7% (42/49). Pulpotomy failed in seven teeth (14.3%). The treatment success rate for traumatic crown fracture was lower than for dental caries and dens evaginatus (P < 0.001). There were no significant differences in the success rate of the pulp-capping agent, tooth root developmental phase, and pulpotomy method (all P > 0.05). Pulpotomy might be successfully used to treat immature permanent teeth with irreversible pulpitis in young patients mainly caused by caries and a fractured tubercle of dens evaginatus.
- 16 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Open AccessPulpotomy for teeth with irreversible pulpitis in immature permanent teeth: a retrospective case series study
To evaluate the success of pulpotomy in treating immature permanent teeth with irreversible pulpitis. This case series included patients with irreversible pulpitis admitted to the Department of Oral Medicine at the author’s Hospital between 2015 and 2020. The pulpotomies were carried out by clinicians with > 5 years of working experience. The follow-up findings and radiographic images were reviewed by two attending dentists. This study included 49 teeth from 48 children (25 boys and 23 girls). The follow-up was 23.3 ± 6.8 months (from 12 to 40 months). The success rate of pulpotomy was 85.7% (42/49). Pulpotomy failed in seven teeth (14.3%). The treatment success rate for traumatic crown fracture was lower than for dental caries and dens evaginatus (P < 0.001). There were no significant differences in the success rate of the pulp-capping agent, tooth root developmental phase, and pulpotomy method (all P > 0.05). Pulpotomy might be successfully used to treat immature permanent teeth with irreversible pulpitis in young patients mainly caused by caries and a fractured tubercle of dens evaginatus.
- Open Access
- 2 November 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1271252
The anti-leukemia activity and mechanisms of shikonin: a mini review
Leukemia encompasses a group of highly heterogeneous diseases that pose a serious threat to human health. The long-term outcome of patients with leukemia still needs to be improved and new effective therapeutic strategies continue to be an unmet clinical need. Shikonin (SHK) is a naphthoquinone derivative that shows multiple biological function includes anti-tumor, anti-inflammatory, and anti-allergic effects. Numerous studies have reported the anti-leukemia activity of SHK during the last 3 decades and there are studies showing that SHK is particularly effective towards various leukemia cells compared to solid tumors. In this review, we will discuss the anti-leukemia effect of SHK and summarize the underlying mechanisms. Therefore, SHK may be a promising agent to be developed as an anti-leukemia drug.
- 2 November 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1271252
Open AccessThe anti-leukemia activity and mechanisms of shikonin: a mini review
Leukemia encompasses a group of highly heterogeneous diseases that pose a serious threat to human health. The long-term outcome of patients with leukemia still needs to be improved and new effective therapeutic strategies continue to be an unmet clinical need. Shikonin (SHK) is a naphthoquinone derivative that shows multiple biological function includes anti-tumor, anti-inflammatory, and anti-allergic effects. Numerous studies have reported the anti-leukemia activity of SHK during the last 3 decades and there are studies showing that SHK is particularly effective towards various leukemia cells compared to solid tumors. In this review, we will discuss the anti-leukemia effect of SHK and summarize the underlying mechanisms. Therefore, SHK may be a promising agent to be developed as an anti-leukemia drug.
- 16 August 2023
- Published by Elsevier in Medicina Clinica
- Vol. 162 (1) , 1-8
Anti-parietal cell antibodies as a potential biomarker for interstitial lung disease associated with primary Sjögren's syndrome
- 16 August 2023
- Published by Elsevier in Medicina Clinica
- Vol. 162 (1) , 1-8
Anti-parietal cell antibodies as a potential biomarker for interstitial lung disease associated with primary Sjögren's syndrome
- Open Access
- 1 April 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 810620
Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia
Thrombocytopenia is a multifactorial condition that frequently involves concomitant defects in platelet production and clearance. The physiopathology of low platelet count in thrombocytopenia remains unclear. Sialylation on platelet membrane glycoprotein and follicular helper T cells (TFHs) are thought to be the novel platelet clearance pathways. The aim of this study was to clarify the roles of platelet desialylation and circulating TFHs in patients with immune thrombocytopenia (ITP) and non-ITP thrombocytopenia. We enrolled 190 patients with ITP and 94 patients with non-ITP related thrombocytopenia including case of aplastic anemia (AA) and myelodysplastic syndromes (MDS). One hundred and ten healthy volunteers were included as controls. We found significantly increased desialylated platelets in patients with ITP or thrombocytopenia in the context of AA and MDS. Platelet desialylation was negatively correlated with platelet count. Meanwhile, the circulating TFH levels in patients with thrombocytopenia were significantly higher than those of normal controls, and were positively correlated with desialylated platelet levels. Moreover, TFHs-related chemokine CXCL13 and apoptotic platelet levels were abnormally high in ITP patients. The upregulation of pro-apoptotic proteins and the activation of the MAPK/mTOR pathway were observed in the same cohort. These findings suggested that platelet desialylation and circulating TFHs may become the potential biomarkers for evaluating the disease process associated with thrombocytopenia in patients with ITP and non-ITP.
- 1 April 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 810620
Open AccessAssociation of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia
Thrombocytopenia is a multifactorial condition that frequently involves concomitant defects in platelet production and clearance. The physiopathology of low platelet count in thrombocytopenia remains unclear. Sialylation on platelet membrane glycoprotein and follicular helper T cells (TFHs) are thought to be the novel platelet clearance pathways. The aim of this study was to clarify the roles of platelet desialylation and circulating TFHs in patients with immune thrombocytopenia (ITP) and non-ITP thrombocytopenia. We enrolled 190 patients with ITP and 94 patients with non-ITP related thrombocytopenia including case of aplastic anemia (AA) and myelodysplastic syndromes (MDS). One hundred and ten healthy volunteers were included as controls. We found significantly increased desialylated platelets in patients with ITP or thrombocytopenia in the context of AA and MDS. Platelet desialylation was negatively correlated with platelet count. Meanwhile, the circulating TFH levels in patients with thrombocytopenia were significantly higher than those of normal controls, and were positively correlated with desialylated platelet levels. Moreover, TFHs-related chemokine CXCL13 and apoptotic platelet levels were abnormally high in ITP patients. The upregulation of pro-apoptotic proteins and the activation of the MAPK/mTOR pathway were observed in the same cohort. These findings suggested that platelet desialylation and circulating TFHs may become the potential biomarkers for evaluating the disease process associated with thrombocytopenia in patients with ITP and non-ITP.
- 11 October 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (11) , 1427-1439
Multiple brain abscesses due to Listeria monocytogenes infection in a patient with systemic lupus erythematosus: A case report and literature review
Aim To review the clinical features of systemic lupus erythematosus (SLE) complicated by central nervous system (CNS) infection due to Listeria monocytogenes. Method A patient with SLE receiving high-dose glucocorticoids combined with cyclophosphamide who developed multiple brain abscesses due to Listeria infection is described. The case is compared with known cases in a literature review. Results A review of the literature showed that CNS infections are rare bacterial complications of SLE, but they can be a significant cause of mortality, especially those due to L. monocytogenes. The most significant risk factor for listerial meningitis is a prior history of receiving immunosuppressive therapy. At-risk patients should avoid unpasteurized milk and soft cheeses along with deli-style, ready-to-eat prepared meats, particularly poultry products. The case we report is the fifth SLE patient with multiple brain abscesses due to L. monocytogenes, and the first to be discharged with no sequelae. Timely and accurate identification and treatment of CNS infections and neuropsychiatric lupus are very important for favorable disease prognosis. Conclusion Repeated blood culture is helpful for early diagnosis, and empirical anti-infective treatment that covers L. monocytogenes is recommended for SLE patients with risk factors when CNS infection occurs. A comprehensive assessment might be helpful to distinguish CNS infections from neuropsychiatric SLE. For severe infection, the dosage of steroids does not need to be reduced immediately but can be gradually adjusted based on the results of a comprehensive evaluation of the disease.
- 11 October 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (11) , 1427-1439
Multiple brain abscesses due to Listeria monocytogenes infection in a patient with systemic lupus erythematosus: A case report and literature review
Aim To review the clinical features of systemic lupus erythematosus (SLE) complicated by central nervous system (CNS) infection due to Listeria monocytogenes. Method A patient with SLE receiving high-dose glucocorticoids combined with cyclophosphamide who developed multiple brain abscesses due to Listeria infection is described. The case is compared with known cases in a literature review. Results A review of the literature showed that CNS infections are rare bacterial complications of SLE, but they can be a significant cause of mortality, especially those due to L. monocytogenes. The most significant risk factor for listerial meningitis is a prior history of receiving immunosuppressive therapy. At-risk patients should avoid unpasteurized milk and soft cheeses along with deli-style, ready-to-eat prepared meats, particularly poultry products. The case we report is the fifth SLE patient with multiple brain abscesses due to L. monocytogenes, and the first to be discharged with no sequelae. Timely and accurate identification and treatment of CNS infections and neuropsychiatric lupus are very important for favorable disease prognosis. Conclusion Repeated blood culture is helpful for early diagnosis, and empirical anti-infective treatment that covers L. monocytogenes is recommended for SLE patients with risk factors when CNS infection occurs. A comprehensive assessment might be helpful to distinguish CNS infections from neuropsychiatric SLE. For severe infection, the dosage of steroids does not need to be reduced immediately but can be gradually adjusted based on the results of a comprehensive evaluation of the disease.
- Open Access
- 2 October 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Predictive model for the probability of malignancy in solitary pulmonary nodules: A meta-analysis
INPLASY2021100006 Predictive model for the probability of malignancy in solitary pulmonary nodules: A meta-analysis Keywords: SPN; predictive model. Download PDF – 2021100006 Review Status: O…
- 2 October 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessPredictive model for the probability of malignancy in solitary pulmonary nodules: A meta-analysis
INPLASY2021100006 Predictive model for the probability of malignancy in solitary pulmonary nodules: A meta-analysis Keywords: SPN; predictive model. Download PDF – 2021100006 Review Status: O…
- Open Access
- 28 September 2021
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 2 (2) , 63-78
2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a severe complication of connective tissue disease (CTD) and is one of the leading causes of morbidity and mortality among patients with this condition. To establish an expert-based consensus on the diagnosis and treatment of CTD-associated PAH, a multidisciplinary consensus development panel was established. The consensus panel is composed of 45 experts in rheumatology, cardiology, pulmonology, and radiology, most of whom are members of the Group of Pulmonary Vascular and Interstitial Lung Diseases (ILD) Associated with Rheumatic Diseases. The consensus development panel compiled 9 recommendations for the diagnosis and treatment of CTD-associated PAH. It covers screening, diagnosis, disease evaluation, risk assessment, the use of immunosuppressive agents, and PAH-specific therapy with a treat-to-target approach. The consensus is intended to facilitate decision-making and standardize the care of CTD-associated PAH in China.
- 28 September 2021
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 2 (2) , 63-78
Open Access2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a severe complication of connective tissue disease (CTD) and is one of the leading causes of morbidity and mortality among patients with this condition. To establish an expert-based consensus on the diagnosis and treatment of CTD-associated PAH, a multidisciplinary consensus development panel was established. The consensus panel is composed of 45 experts in rheumatology, cardiology, pulmonology, and radiology, most of whom are members of the Group of Pulmonary Vascular and Interstitial Lung Diseases (ILD) Associated with Rheumatic Diseases. The consensus development panel compiled 9 recommendations for the diagnosis and treatment of CTD-associated PAH. It covers screening, diagnosis, disease evaluation, risk assessment, the use of immunosuppressive agents, and PAH-specific therapy with a treat-to-target approach. The consensus is intended to facilitate decision-making and standardize the care of CTD-associated PAH in China.
- 2 May 2021
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 171, 203-218
Recent advances in Extracellular Vesicles and their involvements in vasculitis
- 2 May 2021
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 171, 203-218
Recent advances in Extracellular Vesicles and their involvements in vasculitis